CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.15
3.96%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Bioventus Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.28
Open* 3.26
1-Year Change* -53.3%
Day's Range* 3.08 - 3.31
52 wk Range 0.80-8.56
Average Volume (10 days) 325.09K
Average Volume (3 months) 9.18M
Market Cap 260.10M
P/E Ratio -100.00K
Shares Outstanding 78.58M
Revenue 510.62M
EPS -3.61
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Nov 6, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 29, 2023 3.28 0.29 9.70% 2.99 3.30 2.99
Sep 28, 2023 2.99 0.04 1.36% 2.95 3.07 2.90
Sep 27, 2023 2.99 0.05 1.70% 2.94 3.01 2.88
Sep 26, 2023 2.92 0.07 2.46% 2.85 3.00 2.82
Sep 25, 2023 2.92 0.02 0.69% 2.90 2.96 2.80
Sep 22, 2023 2.91 0.05 1.75% 2.86 2.94 2.85
Sep 21, 2023 2.88 -0.14 -4.64% 3.02 3.03 2.85
Sep 20, 2023 3.05 -0.04 -1.29% 3.09 3.14 3.01
Sep 19, 2023 3.07 0.06 1.99% 3.01 3.12 3.01
Sep 18, 2023 3.02 0.05 1.68% 2.97 3.06 2.96
Sep 15, 2023 3.01 0.01 0.33% 3.00 3.04 2.95
Sep 14, 2023 3.04 -0.03 -0.98% 3.07 3.13 3.01
Sep 13, 2023 3.08 -0.01 -0.32% 3.09 3.14 3.03
Sep 12, 2023 3.10 0.01 0.32% 3.09 3.20 3.09
Sep 11, 2023 3.16 0.06 1.94% 3.10 3.23 3.09
Sep 8, 2023 3.11 -0.08 -2.51% 3.19 3.26 3.04
Sep 7, 2023 3.29 -0.06 -1.79% 3.35 3.37 3.19
Sep 6, 2023 3.42 -0.04 -1.16% 3.46 3.52 3.35
Sep 5, 2023 3.51 0.02 0.57% 3.49 3.60 3.35
Sep 1, 2023 3.50 -0.02 -0.57% 3.52 3.67 3.50

Bioventus Inc. Events

Time (UTC) Country Event
Monday, November 6, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 Bioventus Inc Earnings Release
Q3 2023 Bioventus Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 512.117 430.898 321.161 340.141 319.177
Revenue 512.117 430.898 321.161 340.141 319.177
Cost of Revenue, Total 181.037 128.192 87.642 90.935 84.168
Gross Profit 331.08 302.706 233.519 249.206 235.009
Total Operating Expense 763.165 420.999 295.801 311.933 293.673
Selling/General/Admin. Expenses, Total 332.606 254.253 187.469 198.206 191.672
Research & Development 25.941 19.039 11.202 11.055 8.095
Depreciation / Amortization 21.153 8.363 7.439 7.908 8.615
Unusual Expense (Income) 195.976 10.323 2.049 3.829 1.862
Other Operating Expenses, Total 6.452 0.829 0 0 -0.739
Operating Income -251.048 9.899 25.36 28.208 25.504
Interest Income (Expense), Net Non-Operating -24.692 1.77 -9.091 -17.891 -18.66
Other, Net 11.841 -4.049 -0.355 -0.628 -0.737
Net Income Before Taxes -263.899 7.62 15.914 9.689 6.107
Net Income After Taxes -213.391 9.586 14.722 8.113 4.443
Minority Interest 54.687 9.789 1.689 0.553 0
Net Income Before Extra. Items -158.704 19.375 16.411 8.666 4.443
Total Extraordinary Items 0 0 -1.815 -16.65
Net Income -158.704 19.375 16.411 6.851 -12.207
Total Adjustments to Net Income -12.028 -7.51 -5.781
Income Available to Common Excl. Extra. Items -158.704 19.375 4.383 1.156 -1.338
Income Available to Common Incl. Extra. Items -158.704 19.375 4.383 -0.659 -17.988
Diluted Net Income -158.704 19.375 4.383 -0.659 -17.988
Diluted Weighted Average Shares 61.3891 45.4725 55.6253 55.6253 55.6253
Diluted EPS Excluding Extraordinary Items -2.58521 0.42608 0.0788 0.02078 -0.02405
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.0549 1.03994 0.20655 0.16588 0.0261
Jul 2023 Apr 2023 Dec 2022 Oct 2022 Jul 2022
Total revenue 137.069 119.059 125.834 128.662 140.331
Revenue 137.069 119.059 125.834 128.662 140.331
Cost of Revenue, Total 47.946 45.14 51.645 44.127 43.677
Gross Profit 89.123 73.919 74.189 84.535 96.654
Total Operating Expense 130.319 211.117 151.269 329.517 143.639
Selling/General/Admin. Expenses, Total 74.844 80.858 77.668 79.194 89.62
Research & Development 3.398 3.771 6.807 5.84 6.366
Depreciation / Amortization 2.294 2.129 7.761 7.442 2.696
Operating Income 6.75 -92.058 -25.435 -200.855 -3.308
Interest Income (Expense), Net Non-Operating -10.587 -9.694 -14.873 -9.894 -2.579
Other, Net -0.513 1.588 -9.406 23.272 -0.603
Net Income Before Taxes -4.35 -100.164 -49.714 -187.477 -6.49
Net Income After Taxes -4.731 -100.018 -44.873 -145.698 -7.734
Minority Interest 1.05 20.36 12.943 37.453 0.762
Net Income Before Extra. Items -3.681 -79.658 -31.93 -108.245 -6.972
Net Income -3.681 -139.15 -31.93 -108.245 -7.252
Income Available to Common Excl. Extra. Items -3.681 -79.658 -31.93 -108.245 -6.972
Income Available to Common Incl. Extra. Items -3.681 -139.15 -31.93 -108.245 -7.252
Diluted Net Income -3.681 -139.15 -31.93 -108.245 -7.252
Diluted Weighted Average Shares 62.5513 62.1247 61.9296 61.6743 61.4753
Diluted EPS Excluding Extraordinary Items -0.05885 -1.28223 -0.51559 -1.75511 -0.11341
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.04562 -0.34997 -0.29682 0.33166 -0.02298
Unusual Expense (Income) 1.597 78.932 4.62 189.772 1.007
Other Operating Expenses, Total 0.24 0.287 2.768 3.142 0.273
Total Extraordinary Items 0 -59.492 -0.28
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 272.575 263.103 211.794 183.033 148.354
Cash and Short Term Investments 31.814 43.933 86.839 64.52 42.774
Cash & Equivalents 31.814 43.933 86.839 64.52 42.774
Total Receivables, Net 136.912 125.045 88.364 85.389 73.041
Accounts Receivable - Trade, Net 136.912 125.045 88.364 85.389 73.041
Total Inventory 85.408 61.688 29.12 27.326 27.396
Prepaid Expenses 18.418 27.157 7.471 5.798 4.713
Other Current Assets, Total 0.023 5.28 0.43
Total Assets 1372.65 1225.86 494.466 472.407 442.723
Property/Plant/Equipment, Total - Net 44.955 40.171 21.84 19.756 4.759
Property/Plant/Equipment, Total - Gross 75.827 52.818 42.161 37.998 23.515
Accumulated Depreciation, Total -30.872 -23.1 -20.321 -18.242 -18.756
Goodwill, Net 13.759 147.623 49.8 49.8 49.8
Intangibles, Net 1038.72 695.193 191.65 216.51 237.029
Long Term Investments 2.636 29.291 19.382 3.308 2.781
Total Current Liabilities 304.017 180.859 122.589 89.015 65.428
Accounts Payable 37.549 16.915 4.422 6.44 8.207
Accrued Expenses 113.11 137.713 98.767 67.633 48.952
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 33.056 18.038 15 10.041 5.25
Other Current Liabilities, Total 120.302 8.193 4.4 4.901 3.019
Total Liabilities 1056.07 766.938 352.225 329.425 297.456
Total Long Term Debt 385.01 339.644 173.378 187.978 189.578
Long Term Debt 385.01 339.644 173.378 187.965 189.578
Deferred Income Tax 154.001 133.518 3.362 3.874 3.955
Minority Interest 23.751 74.865 1.919 2.635 0
Other Liabilities, Total 189.289 38.052 50.977 45.923 38.495
Total Equity 316.581 458.924 142.241 142.982 145.267
Redeemable Preferred Stock 210.576 204.443 198.488
Preferred Stock - Non Redeemable, Net -42.576 -36.443 -30.488
Common Stock 0.078 0.075 113.373 113.373 113.373
Retained Earnings (Accumulated Deficit) -165.306 -6.602 -140.739 -137.926 -136.041
Other Equity, Total -0.11 0.179 1.607 -0.465 -0.065
Total Liabilities & Shareholders’ Equity 1372.65 1225.86 494.466 472.407 442.723
Total Common Shares Outstanding 77.8497 75.3352 55.6253 55.6253 55.6253
Capital Lease Obligations 0.013
Other Long Term Assets, Total 0 50.481
Additional Paid-In Capital 481.919 465.272
Apr 2023 Dec 2022 Oct 2022 Jul 2022 Apr 2022
Total Current Assets 308.664 272.575 271.082 277.157 245.395
Cash and Short Term Investments 47.102 31.814 34.359 41.001 27.374
Cash & Equivalents 47.102 31.814 34.359 41.001 27.374
Total Receivables, Net 118.544 136.912 132.185 143.018 119.288
Accounts Receivable - Trade, Net 118.544 136.912 132.185 143.018 119.288
Total Inventory 87.953 85.408 76.952 69.078 64.691
Prepaid Expenses 17.192 18.418 27.563 24.06 28.762
Other Current Assets, Total 37.873 0.023 0.023 0 5.28
Total Assets 887.404 1372.65 1398.02 1208.78 1197.14
Property/Plant/Equipment, Total - Net 52.619 44.955 42.947 43.454 43.594
Goodwill, Net 7.462 13.759 15.359 143.156 147.968
Intangibles, Net 516.039 1038.72 1055.6 666.523 681.369
Long Term Investments 2.62 2.636 13.033 78.486 28.811
Other Long Term Assets, Total 0 0 0 50
Total Current Liabilities 196.063 304.017 288.373 198.873 171.522
Accounts Payable 32.828 37.549 19.075 25.735 22.5
Accrued Expenses 115.127 113.11 118.025 123.833 112.94
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 41.32 33.056 31.302 22.547 20.292
Other Current Liabilities, Total 6.788 120.302 119.971 26.758 15.79
Total Liabilities 698.893 1056.07 1054.62 760.795 747.361
Total Long Term Debt 404.265 385.01 393.102 351.433 348.039
Long Term Debt 404.265 385.01 393.102 351.433 348.039
Deferred Income Tax 0.351 154.001 159.3 98.892 116.02
Minority Interest 51.851 23.751 35.749 72.209 72.142
Other Liabilities, Total 46.363 189.289 178.101 39.388 39.638
Total Equity 188.511 316.581 343.397 447.981 449.776
Common Stock 0.079 0.078 0.08 0.08 0.078
Additional Paid-In Capital 492.475 481.919 478.033 473.796 467.94
Retained Earnings (Accumulated Deficit) -304.456 -165.306 -133.376 -25.131 -17.879
Other Equity, Total 0.413 -0.11 -1.34 -0.764 -0.363
Total Liabilities & Shareholders’ Equity 887.404 1372.65 1398.02 1208.78 1197.14
Total Common Shares Outstanding 78.2946 77.8497 77.5646 77.4432 77.144
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -213.391 9.586 14.722 6.298 -12.207
Cash From Operating Activities -13.537 22.991 71.799 40.713 45.187
Cash From Operating Activities 66.803 34.875 28.643 30.316 29.238
Deferred Taxes -52.792 -9.756 -0.511 -0.348 -0.079
Non-Cash Items 200.375 1.563 13.637 18.019 25.383
Cash Taxes Paid 1.518 7.456 1.541 1.577 1.944
Cash Interest Paid 18.043 5.837 7.486 15.45 17.273
Changes in Working Capital -14.532 -13.277 15.308 -13.572 2.852
Cash From Investing Activities -116.436 -283.76 -20.5 -7.912 -6.101
Capital Expenditures -10.042 -7.37 -4.093 -2.342 -2.561
Other Investing Cash Flow Items, Total -106.394 -276.39 -16.407 -5.57 -3.54
Cash From Financing Activities 62.076 273.371 -29.569 -10.951 -13.256
Financing Cash Flow Items -3.367 -2.242 -19.569 -9.504 -7.846
Issuance (Retirement) of Debt, Net 59.621 166.203 -10 -1.447 -5.41
Foreign Exchange Effects 0.521 -0.228 0.589 -0.104 -0.16
Net Change in Cash -67.376 12.374 22.319 21.746 25.67
Issuance (Retirement) of Stock, Net 5.822 109.41
Apr 2023 Dec 2022 Oct 2022 Jul 2022 Apr 2022
Net income/Starting Line -174.447 -213.391 -168.518 -22.82 -14.806
Cash From Operating Activities 2.49 -13.537 -18.781 -18.08 -21.019
Cash From Operating Activities 16.473 66.803 43.643 24.863 12.479
Deferred Taxes -2.664 -52.792 -47.154 -27.698 -17.018
Non-Cash Items 155.058 200.375 183.873 9.784 2.633
Changes in Working Capital 8.07 -14.532 -30.625 -2.209 -4.307
Cash From Investing Activities -15.066 -116.436 -113.033 -56.699 -4.674
Capital Expenditures -3.56 -10.042 -6.639 -4.99 -2.96
Other Investing Cash Flow Items, Total -11.506 -106.394 -106.394 -51.709 -1.714
Cash From Financing Activities 27.38 62.076 67.514 16.86 9.205
Financing Cash Flow Items -1.704 -3.367 -3.356 -3.378 -3.366
Issuance (Retirement) of Stock, Net 0.084 5.822 4.739 4.257 2.08
Issuance (Retirement) of Debt, Net 29 59.621 66.131 15.981 10.491
Foreign Exchange Effects 0.461 0.521 -0.531 -0.293 -0.071
Net Change in Cash 15.265 -67.376 -64.831 -58.212 -16.559

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Bioventus Inc. Company profile

About Bioventus Inc

Bioventus Inc is a global medical device company. The Company is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Bioventus Inc revenues increased 34% to $430.9M. Net income applicable to common stockholders increased from $4.4M to $19.4M. Revenues reflect U.S. segment increase of 32% to $387.6M, International segment increase of 58% to $43.3M. Net income benefited from Stock-based Compensation in SGA decrease from $10.1M (expense) to $4.5M (income), Foreign Exchange Gain/Loss increase of 13% to $132K (income).

Industry: Medical Equipment

4721 Emperor Boulevard, Suite 100
DURHAM
NORTH CAROLINA 27703
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

US100

14,849.40 Price
+0.730% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.52 Price
-0.410% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Oil - Crude

87.97 Price
-2.240% 1D Chg, %
Long position overnight fee 0.0589%
Short position overnight fee -0.0808%
Overnight fee time 21:00 (UTC)
Spread 0.030

Gold

1,827.76 Price
-1.100% 1D Chg, %
Long position overnight fee -0.0195%
Short position overnight fee 0.0113%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading